Stock Taper
SCREENER COMPARE ANY 2 STOCKS
HIND
VYOME HOLDINGS, INC.
NASDAQ
$2.25
▼ DOWN 1.32% (-0.03)

KEY STATISTICS

Market Cap$15.79 M
52w High$12.00
52w Low$1.75
Dividend Yield—
Frequency—
P/E-0.38
Volume4.39K
Shares Out.7.02M

COMPANY

LEADERSHIP

Venkateswarlu Nelabhotla
CHIEF EXECUTIVE
Venkateswarlu Nelabhotla

COMPENSATION 2026

Salary$260,000
Stock Awards$208,302
Incentive Plan Pay$0
All Other Comp.$10,409
Total$478,711

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 6, 2016
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
18

PRICE TARGET

Target High$15.00
Target Low$15.00
Target Median$15.00
Target Consensus$15.00

UPCOMING EARNINGS

DateNov 13, 2026
DayFriday
Rev. Est.$24.11K
NOV
13
FRI

SPLIT RECORD

DATETYPERATIO
2025-08-15Reverse1:4
2025-05-09Reverse1:25
2024-09-23Reverse1:58
2022-12-23Reverse1:50
2021-06-16Reverse1:3
2019-11-12Reverse1:120
2019-07-25Reverse1:10
2018-11-08Reverse1:140
2018-06-04Reverse1:15
2016-12-28Reverse1:70

PRICE

$2.25 ▼ DOWN 1.32% (−$0.03)
OVERLAYS
$2.24$2.28$2.329:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM2.25

About Vyome Holdings, Inc.

https://www.vyometx.com ↗

Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Princeton, New Jersey.

INDUSTRY

Biotechnology

A PRODUCT VYOME HOLDINGS, INC. IS KNOWN FOR

VT-1953
VT-1953

VT-1953 is a novel topical gel in clinical development for Malignant Fungating Wounds in advanced cancer patients, with recent efforts focused on advancing Phase 3 trials, securing funding, and pursuing orphan drug status.

COMPETITORS

COMPETITOR
ARQT COMPARE
MANE COMPARE
VY VYNE COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$26.97K $147.67K ▲$25.46K ▼$50.28K ▲
Royalty$7.65K $20.52K ▲$6.13K ▼$8.26K ▲
License$116.9K $0 ▼— —

Revenue by Geography

MapREGIONQ3-2024Q4-2024Q1-2025Q2-2025
UNITED STATES$2.01M $3.21M ▲$931K ▼$1.09M ▲
Europe$168K $123K ▼$98K ▼$81K ▼
AUSTRALIA$111K $178K ▲$78K ▼$68K ▼
NonUS$4K $35K ▲$6K ▼$1K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
VXF
0.00% · 9.5K

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
DIRECTOR
Pomichter Stanley D III
Purchase · 17.8K shares
2025-11-13
★
DIRECTOR:
Pomichter Stanley D III
— · —
2025-08-15
★
DIRECTOR
Jolly Mohanjit
Purchase · 454.5K shares
2025-08-15
★
DIRECTOR:
Jolly Mohanjit
— · —
2025-08-15

SECTORS PEERS

PEERPRICE
OABI$4.33COMPARE
NVCT$23.56COMPARE
CCCC$4.00COMPARE
CGEN$2.62COMPARE
IPHA$2.26COMPARE
TNXP$12.55COMPARE
CDXS$1.67COMPARE
IMDX$4.34COMPARE